Understanding Impurities In Drug Substances Products Global Guidances Usp Perspective
Welcome to our comprehensive guide on Impurities In Drug Substances Products Global Guidances Usp Perspective. This is an edited version of the webinar aired live on October 26, 2021. Speaker is Christian Zeine, Scientific Affairs Manager.
Key Takeaways about Impurities In Drug Substances Products Global Guidances Usp Perspective
- On September 2, 2020, FDA published a
- This webinar aired live October 13, 2020. Speaker is Naiffer Romero, Senior Scientific Affairs Manager. Naiffer explains about the ...
- Mitchell Frost from CDER's Office of Generic
- nitrosamines #
- Submit proposed questions on this poster to DMFWorkshop2021@fda.hhs.gov by March 19, 2021, and tune in for the subsequent ...
Detailed Analysis of Impurities In Drug Substances Products Global Guidances Usp Perspective
Regis' Director of Analytical Method Development, Dr. Paul Wrezel, repurposes his Pittcon 2015 talk for a Regis audience. This is ... FDA discusses the OGD-Pharmacology/Toxicology (Pharm/Tox) process for safety evaluation of This presentation provided an overview of the current regulatory landscape surrounding nitrosamines and the latest
CDER's Office of
In summary, understanding Impurities In Drug Substances Products Global Guidances Usp Perspective gives us a better perspective.